CorrespondenceBeneficial effects and reversion of vascular lesions by thalidomide in a patient with bleeding portal hypertensive enteropathy
Section snippets
Conflict of interest
None declared.
References (5)
- et al.
Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study
Gastrointest Endosc
(2005) - et al.
Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats
Hepatology
(1996)
There are more references available in the full text version of this article.
Cited by (11)
Portal hypertensive enteropathy:A disease that should not be ignored among the complications of portal hypertension
2022, Journal of Clinical HepatologyEmerging role of thalidomide in the treatment of gastrointestinal bleeding
2018, Frontline GastroenterologyDiagnostic and therapeutic features of small bowel involvement in portal hypertension
2017, Revista Espanola de Enfermedades DigestivasCapsule endoscopy for portal hypertensive enteropathy
2016, Gastroenterology Research and PracticeThalidomide in angiodysplasia-related bleeding
2015, Internal Medicine Journal
Copyright © 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.